NCT06498648 2026-03-18
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
19 trialsNCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07100106 2026-03-12
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Genentech, Inc.
Phase 1/2 Recruiting
NCT06188520 2026-02-24
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT04923542 2026-02-06
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT05386108 2026-02-05
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06810544 2026-02-02
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04941274 2026-01-23
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06835972 2026-01-15
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05608252 2025-10-29
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05735080 2025-09-19
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT05113537 2025-09-18
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT05095207 2025-04-02
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT06594679 2025-03-28
NICHOL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT04092673 2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2 Recruiting